Headlands Technologies’s Esperion Therapeutics ESPR Stock Holding History

Headlands Technologies’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,157	Closed	-$38.8K	–	799
2026 Q1	$38.8K	Sell	14,157 -206,931	-94%	-$655K	﹤0.01%	705
2025 Q4	$818K	Buy	221,088 +124,830	+130%	+$403K	0.07%	300
2025 Q3	$255K	Buy	+96,258	New	+$186K	0.02%	500
2025 Q2	–	Sell	-38,447	Closed	-$55.4K	–	1287
2025 Q1	$55.4K	Sell	38,447 -216,619	-85%	-$399K	0.01%	696
2024 Q4	$561K	Buy	255,066 +90,522	+55%	+$211K	0.06%	324
2024 Q3	$271K	Sell	164,544 -111,716	-40%	-$226K	0.03%	450
2024 Q2	$613K	Buy	+276,260	New	+$650K	0.07%	242
2024 Q1	–	Sell	-3,208	Closed	-$9.59K	–	1323
2023 Q4	$9.59K	Buy	+3,208	New	+$4.16K	﹤0.01%	762
2023 Q3	–	Sell	-2,110	Closed	-$2.93K	–	1009
2023 Q2	$2.93K	Buy	+2,110	New	+$2.95K	﹤0.01%	704

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Headlands Technologies's ESPR Position: Q2 2026 in Review

Headlands Technologies sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 14,157 shares — an estimated $38.8K sold.

Headlands Technologies first reported a position in ESPR in Q2 2023 and held it in 9 quarters. The position peaked at $818K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Headlands Technologies reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Headlands Technologies sold 14,157 Esperion Therapeutics shares in Q2 2026, an estimated $38.8K.
Headlands Technologies first reported a position in Esperion Therapeutics in Q2 2023 and held it in 9 quarters.
Headlands Technologies's Esperion Therapeutics position peaked at $818K in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.